OverviewSuggest Edit

Bioblast Pharma Ltd. built on the premise of discovering, developing, and delivering clinically meaningful therapies for patients with rare diseases. Given the interest in the scientific and medical community regarding alternative therapeutic uses of the Company's lead drug candidate, trehalose 90 mg/mL IV solution, Bioblast has decided to concentrate internal development efforts exclusively on trehalose. 

... Show more
TypePublic
Founded2012
HQTel Aviv-Yafo, IL
Websitebioblastpharma.com

Latest Updates

Employees (est.) (Jun 2017)12
Revenue (FY, 2017)$0
Share Price (Feb 2019)$1.2 (+7%)

Bioblast Pharma Office Locations

Bioblast Pharma has an office in Tel Aviv-Yafo
Show all (1)
Report incorrect company information

Bioblast Pharma Financials and Metrics

Bioblast Pharma Revenue

USD

Net income (FY, 2017)

(5.9m)

EBIT (FY, 2017)

(6.0m)

Market capitalization (12-Feb-2019)

3.9m

Closing stock price (12-Feb-2019)

1.2

Cash (31-Dec-2017)

3.5m
Bioblast Pharma's current market capitalization is $3.9 m.
USDFY, 2015FY, 2016FY, 2017

Sales and marketing expense

829.0k1.1m479.0k

General and administrative expense

7.0m5.9m3.0m

R&D expense

7.7m8.9m2.5m
USDFY, 2015FY, 2016FY, 2017

Cash

7.3m6.9m3.5m

Prepaid Expenses

1.1m663.0k96.0k

Current Assets

20.4m10.5m3.6m

PP&E

91.0k71.0k
USDFY, 2015FY, 2016FY, 2017

Net Income

(15.4m)(16.0m)(5.9m)

Depreciation and Amortization

17.0k38.0k64.0k

Accounts Payable

107.0k129.0k(790.0k)

Cash From Operating Activities

(13.2m)(15.5m)(6.4m)
USDY, 2017

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Bioblast Pharma News and Updates

Bioblast Pharma Announces Collaboration with Team Sanfilippo to Evaluate Trehalose for the Treatment of Sanfilippo Syndrome

Tel Aviv, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome today…

Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance

Tel Aviv, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq …

Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors

TEL AVIV, Israel, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq: ORPN) announced the execution of a definitive agreement to acquire Enlivex Therapeutics Ltd., a VC-funded privately-held immunotherapy company. Upon closing of the transaction, the combined company will change its na…
Report incorrect company information

Bioblast Pharma Company Life and Culture

Report incorrect company information

Bioblast Pharma Frequently Asked Questions

  • When was Bioblast Pharma founded?

    Bioblast Pharma was founded in 2012.

  • How many employees does Bioblast Pharma have?

    Bioblast Pharma has 12 employees.

  • Who are Bioblast Pharma competitors?

    Competitors of Bioblast Pharma include Ultragenyx Pharmaceutical, Aevi Genomic Medicine and Vical.

  • Where are Bioblast Pharma offices?

    Bioblast Pharma has an office in Tel Aviv-Yafo.

  • How many offices does Bioblast Pharma have?

    Bioblast Pharma has 1 office.